Bliesath, et al. 46 found that CK2 and EGFR signaling could cooperate to promote oncogenic signaling in NSCLC, and they further demonstrated that the synergistic combination of a CK2 inhibitor with EGFR antagonists reduced tumor size in a murine NSCLC xenograft. The gene discussed is EGFR; the disease is neoplasm.